A Phase 2 Study of TRS005 in Patients with CD20-positive R/R DLBCL.
Phase 2
Not yet recruiting
- Conditions
- CD20-positive Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT06886139
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Cancer Hospital, Beijing, Beijing, China
A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.
Phase 1
Recruiting
- Conditions
- CD20-positive B-cell Non-Hodgkin Lymphoma
- Interventions
- Drug: Recombinant CD20 monoclonal antibody-MMAE conjugte for injection
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT05395533
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University), Zhengzhou, Henan, China
🇨🇳Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC
Phase 3
- Conditions
- Metastatic Colorectal Cancer (CRC)
- Interventions
- Biological: TRS003Biological: China-approved BevacizumabDrug: mFOLFOX6
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT05378867
A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC
Phase 3
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
- Target Recruit Count
- 608
- Registration Number
- NCT04416035
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital of Xingtai Medical College, Xingtai, Hebei, China
🇨🇳FAW General Hospital of Jilin Province, Changchun, Jilin, China
A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: TRS003Biological: China-approved BevacizumabBiological: US-licensed Avastin
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT03882424
- Locations
- 🇺🇸
WCCT Global, Inc., Cypress, California, United States
© Copyright 2025. All Rights Reserved by MedPath